drug_type
RELEVANT_DRUG
intervention_type
cellular gene therapy (CAR T cells)
drug_description
Autologous genetically engineered T cells expressing a chimeric antigen receptor targeting CD19 on B-lineage cells; induce cytotoxic depletion of CD19+ naive and memory B cells and plasmablasts to reduce pathogenic autoantibody production in refractory SLE.
nci_thesaurus_concept_id
C176018
nci_thesaurus_preferred_term
Anti-CD19 CAR T Cells Preparation
nci_thesaurus_definition
Any preparation of CAR-T cells that targets CD19.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a CD19-specific chimeric antigen receptor. Upon binding CD19 on B-lineage cells, they activate and kill targets via T-cell cytotoxic mechanisms (perforin/granzyme), depleting CD19+ naive and memory B cells and plasmablasts to reduce pathogenic autoantibody production and B cell–driven autoimmunity.
drug_name
anti-CD19 CAR-T cells
nct_id_drug_ref
NCT06222853